This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The public consultation is open until 31 December 2023 and the topic will be further discussed during a joint HMA/EMA workshop scheduled for 20-21 November 2023. All interested stakeholders are invited to comment on the draft reflection paper and to identify potential opportunities and risks of AI in the field of medicines.
The public consultation is open until 31 December 2023 and the topic will be further discussed during a joint HMA/EMA workshop scheduled for 20-21 November 2023. All interested stakeholders are invited to comment on the draft reflection paper and to identify potential opportunities and risks of AI in the field of medicines.
Participants were from regulatory medicine agencies in low-, middle-, and high-income countries; experts on and developers of screening technologies and other key stakeholders, including the WorldHealth Organization (WHO), Interpol, UNICEF, and the United States Pharmacopeia (USP).
Participants were from regulatory medicine agencies in low-, middle-, and high-income countries; experts on and developers of screening technologies and other key stakeholders, including the WorldHealth Organization (WHO), Interpol, UNICEF, and the United States Pharmacopeia (USP).
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content